Navigation Links
Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review
Date:11/6/2008

NEW ORLEANS and CARLSBAD, Calif., Nov. 6

/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

What: Isis' cardiovascular program review of development and

late-stage research candidates, including presentations

from:

-- Dr. Erik Stroes reporting top line data from an ongoing

Phase 2 mipomersen liver imaging study

-- Dr. Evan Stein providing an update on an open-label

extension study of mipomersen in subjects with familial

hypercholesterolemia

When: Monday, November 10, 2008, at 6:00 p.m. CT (4:00 p.m.

PT/7:00 p.m. ET)

Where: http://www.isispharm.com

How: Live on the Internet. Simply log onto the website listed

above.

Contacts: Kristina Lemonidis

Associate Director, Corporate Development

Isis Pharmaceuticals, Inc.

(760) 603-2490

Amy Blackley, Ph.D.

Manager, Corporate Communications

Isis Pharmaceuticals, Inc.

(760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
2. GNC Schedules Conference Call and Webcast to Report 3rd Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
4. STERIS Corporation Announces Webcast of Analyst Conference
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Third Quarter 2008 Financial Results Call Set for November 11
6. Webcast Alert: Heska Announces Third Quarter 2008 Earnings Conference Call Webcast
7. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Fourth Quarter and Year End Earnings Webcast
9. Sunrise to Host Conference Call and Webcast to Discuss the Companys Financial Results for the Third Quarter 2008
10. Webcast Alert: Air Methods Corporation Announces Third Quarter 2008 Financial Results
11. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: